Review
Weekly chemotherapeutic regimen in metastatic prostate cancer
Affiliations
- PMID: 2201043
Item in Clipboard
Review
Weekly chemotherapeutic regimen in metastatic prostate cancer
Prog Clin Biol Res.
1990.
Abstract
1. A weekly fractionation of EPIRUBICIN at an unchanged dose intensity leads to a significant decrease in toxicity. 2. The weekly administration of 25 mg/m2 EPIRUBICIN is effective in treating hormone refractory prostate carcinoma and completely fulfills the requirements for palliation.
Similar articles
-
Weekly chemotherapeutic regimen in metastatic prostate cancer.Prog Clin Biol Res. 1989;303:261-75. Prog Clin Biol Res. 1989. PMID: 2674989 Review.
-
Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer.Urology. 2007 Jan;69(1):142-6. doi: 10.1016/j.urology.2006.09.015. Urology. 2007. PMID: 17270637 Clinical Trial.
-
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.Cancer Treat Rev. 2008 Dec;34(8):710-8. doi: 10.1016/j.ctrv.2008.05.004. Epub 2008 Jul 11. Cancer Treat Rev. 2008. PMID: 18620815 Review.
-
Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.Eur Urol. 1997;32 Suppl 3:81-5. Eur Urol. 1997. PMID: 9267791 Clinical Trial.
-
Chemotherapy of advanced cancer of the prostate.Prog Clin Biol Res. 1990;350:159-70. Prog Clin Biol Res. 1990. PMID: 2201042 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical